Why AbbVie's Booming 2017 Could Continue in 2018 Post author:Sam Post published:December 14, 2017 Post category:BioPharma Now that 2017 is drawing to an end, though, it’s time to focus on the new year. Source: BioSpace You Might Also Like Vanda Pharmaceuticals’ Hetlioz Shows Promise for Treating Jet Lag March 4, 2018 FDA Approves Genentech's Zelboraf, the First-Ever Drug to Treat Specific Rare Blood Disease November 6, 2017 <b>Repare Therapeutics</b> Bursts From Stealth Mode With $68 Million and a Team Packed With Industry Alums June 21, 2017
FDA Approves Genentech's Zelboraf, the First-Ever Drug to Treat Specific Rare Blood Disease November 6, 2017
<b>Repare Therapeutics</b> Bursts From Stealth Mode With $68 Million and a Team Packed With Industry Alums June 21, 2017
